GB9916882D0
(en)
*
|
1999-07-19 |
1999-09-22 |
Pharmacia & Upjohn Spa |
Antitumor synergistic composition
|
EP1496897A4
(en)
|
2002-04-12 |
2006-05-10 |
Merck & Co Inc |
INHIBITORS OF TYROSINE KINASES
|
CA2494061C
(en)
|
2002-07-31 |
2011-06-14 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
EP1551824B1
(en)
|
2002-10-09 |
2007-12-12 |
Critical Outcome Technologies, Inc. |
Protein tyrosine kinase inhibitors
|
DE10354060A1
(de)
|
2003-11-19 |
2005-06-02 |
Merck Patent Gmbh |
Pyrrolderivate
|
DE10355904A1
(de)
|
2003-11-29 |
2005-06-30 |
Merck Patent Gmbh |
Feste Formen von anti-EGFR-Antikörpern
|
CN100438913C
(zh)
*
|
2004-11-22 |
2008-12-03 |
山东蓝金生物工程有限公司 |
一种抗癌药物组合物
|
CN100402091C
(zh)
*
|
2005-02-03 |
2008-07-16 |
山东蓝金生物工程有限公司 |
一种抗癌药物组合物
|
CN100350974C
(zh)
*
|
2005-02-03 |
2007-11-28 |
山东蓝金生物工程有限公司 |
一种抗癌药物组合物
|
DE102005016634A1
(de)
|
2005-04-12 |
2006-10-19 |
Merck Patent Gmbh |
Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
|
AU2006239632B2
(en)
|
2005-04-25 |
2012-03-15 |
Merck Patent Gmbh |
Novel AZA- heterocycles serving as kinase inhibitors
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
DE102005061840A1
(de)
|
2005-12-23 |
2007-06-28 |
Merck Patent Gmbh |
Triazolderivate
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
CA2664113C
(en)
|
2006-09-22 |
2013-05-28 |
Merck & Co., Inc. |
Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
RU2446796C2
(ru)
|
2006-12-26 |
2012-04-10 |
Фармасайкликс, Инк. |
Способ использования ингибиторов гистондеацетилазы и мониторинга биомаркеров в комбинированной терапии
|
EP2805945B1
(en)
|
2007-01-10 |
2019-04-03 |
MSD Italia S.r.l. |
Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
|
US8138191B2
(en)
|
2007-01-11 |
2012-03-20 |
Critical Outcome Technologies Inc. |
Inhibitor compounds and cancer treatment methods
|
DE102007008419A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
|
AU2008221263B2
(en)
|
2007-03-01 |
2012-02-23 |
Novartis Ag |
Pim kinase inhibitors and methods of their use
|
DE102007013854A1
(de)
|
2007-03-20 |
2008-09-25 |
Merck Patent Gmbh |
Tetrahydrochinoline
|
DE102007013856A1
(de)
|
2007-03-20 |
2008-09-25 |
Merck Patent Gmbh |
Substituierte Tetrahydropyrrolochinoline
|
DE102007013855A1
(de)
|
2007-03-20 |
2008-09-25 |
Merck Patent Gmbh |
Substituierte Tetrahydrochinoline
|
AU2008254425A1
(en)
|
2007-05-21 |
2008-11-27 |
Novartis Ag |
CSF-1R inhibitors, compositions, and methods of use
|
DE102007028515A1
(de)
|
2007-06-21 |
2008-12-24 |
Merck Patent Gmbh |
6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
|
JP5501227B2
(ja)
|
2007-06-27 |
2014-05-21 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ヒストンデアセチラーゼ阻害剤としての4−カルボキシベンジルアミノ誘導体
|
DE102007047737A1
(de)
|
2007-10-05 |
2009-04-30 |
Merck Patent Gmbh |
Piperidin- und Piperazinderivate
|
DE102007047735A1
(de)
|
2007-10-05 |
2009-04-09 |
Merck Patent Gmbh |
Thiazolderivate
|
DE102007047738A1
(de)
|
2007-10-05 |
2009-04-09 |
Merck Patent Gmbh |
Imidazolderivate
|
DE102007049451A1
(de)
|
2007-10-16 |
2009-04-23 |
Merck Patent Gmbh |
5-Cyano-thienopyridine
|
AU2008336249B2
(en)
|
2007-12-10 |
2015-01-29 |
The University Of Queensland |
Treatment and prophylaxis
|
EP2225226B1
(en)
|
2007-12-26 |
2016-08-17 |
Critical Outcome Technologies, Inc. |
Compounds and their use in a method for treatment of cancer
|
DE102008005493A1
(de)
|
2008-01-22 |
2009-07-23 |
Merck Patent Gmbh |
4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
|
DE102008017853A1
(de)
|
2008-04-09 |
2009-10-15 |
Merck Patent Gmbh |
Thienopyrimidine
|
MX2010011168A
(es)
|
2008-04-15 |
2010-12-21 |
Pharmacyclics Inc |
Inhibidores selectivos de histona-desacetilasa.
|
DE102008025751A1
(de)
|
2008-05-29 |
2009-12-03 |
Merck Patent Gmbh |
4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-pyridin-2-ylamin-derivate
|
DE102008027574A1
(de)
|
2008-06-10 |
2009-12-17 |
Merck Patent Gmbh |
Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
|
DE102008031517A1
(de)
|
2008-07-03 |
2010-01-07 |
Merck Patent Gmbh |
Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
|
DE102008059578A1
(de)
|
2008-11-28 |
2010-06-10 |
Merck Patent Gmbh |
Benzo-Naphtyridin Verbindungen
|
DE102009005193A1
(de)
|
2009-01-20 |
2010-07-22 |
Merck Patent Gmbh |
Neue heterocyclische Verbindungen als MetAP-2 Inhibitoren
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
CN102365271B
(zh)
|
2009-04-02 |
2014-05-14 |
默克专利有限公司 |
作为自分泌运动因子抑制剂的杂环化合物
|
MX2011010203A
(es)
|
2009-04-02 |
2011-10-14 |
Merck Patent Gmbh |
Derivados de piperidina y piperazina como inhibidores de autotaxina.
|
ES2547124T3
(es)
|
2009-04-02 |
2015-10-01 |
Merck Patent Gmbh |
Inhibidores de autotaxina
|
DE102009019962A1
(de)
|
2009-05-05 |
2010-11-11 |
Merck Patent Gmbh |
3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
|
WO2010144909A1
(en)
|
2009-06-12 |
2010-12-16 |
Novartis Ag |
Fused heterocyclic compounds and their uses
|
DE102009033208A1
(de)
|
2009-07-15 |
2011-01-20 |
Merck Patent Gmbh |
Aminopyridinderivate
|
DE102009033392A1
(de)
|
2009-07-16 |
2011-01-20 |
Merck Patent Gmbh |
Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
|
ES2745255T3
(es)
|
2009-08-26 |
2020-02-28 |
Alberta Health Services |
Derivados de colchicina novedosos, métodos y usos de los mismos
|
DE102009049211A1
(de)
|
2009-10-13 |
2011-04-28 |
Merck Patent Gmbh |
Sulfoxide
|
JP5099731B1
(ja)
|
2009-10-14 |
2012-12-19 |
メルク・シャープ・アンド・ドーム・コーポレーション |
p53活性を増大する置換ピペリジン及びその使用
|
KR20130025860A
(ko)
|
2009-11-07 |
2013-03-12 |
메르크 파텐트 게엠베하 |
Tgf-베타 수용체 키나아제 저해제로서의 헤테로아릴아미노퀴놀린
|
DE102009060174A1
(de)
|
2009-12-23 |
2011-06-30 |
Merck Patent GmbH, 64293 |
Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
|
DE102009060175A1
(de)
|
2009-12-23 |
2011-06-30 |
Merck Patent GmbH, 64293 |
Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen
|
WO2011090738A2
(en)
|
2009-12-29 |
2011-07-28 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
EA201290919A1
(ru)
|
2010-03-16 |
2013-03-29 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Индазольные соединения и их применение
|
US9029387B2
(en)
|
2010-03-26 |
2015-05-12 |
Merck Patent Gmbh |
Benzonaphthyridinamines as autotaxin inhibitors
|
EP2552915B1
(en)
|
2010-04-01 |
2017-07-19 |
Critical Outcome Technologies Inc. |
Compounds for the treatment of hiv
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
EA201300052A1
(ru)
|
2010-06-28 |
2013-06-28 |
Мерк Патент Гмбх |
[1,8]нафтиридиновые производные
|
EP2590946B1
(en)
|
2010-07-05 |
2015-02-18 |
Merck Patent GmbH |
Bipyridyl derivatives useful for the treatment of kinase-induced diseases
|
EP3330377A1
(en)
|
2010-08-02 |
2018-06-06 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
EP3587574B1
(en)
|
2010-08-17 |
2022-03-16 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
WO2012027236A1
(en)
|
2010-08-23 |
2012-03-01 |
Schering Corporation |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
CN103189378B
(zh)
|
2010-09-02 |
2016-03-02 |
默克专利股份公司 |
作为lpa受体拮抗剂的吡唑并吡啶酮衍生物
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
DE102010048374A1
(de)
|
2010-10-13 |
2012-04-19 |
Merck Patent Gmbh |
Pyrrolidinone als MetAP-2 Inhibitoren
|
EP3327125B1
(en)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
DE102010049877A1
(de)
|
2010-11-01 |
2012-05-03 |
Merck Patent Gmbh |
7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
|
DE102010050558A1
(de)
|
2010-11-05 |
2012-05-10 |
Merck Patent Gmbh |
1H-Pyrrolo[2,3-b]pyridinderivate
|
DE102010053347A1
(de)
|
2010-12-03 |
2012-06-06 |
Merck Patent Gmbh |
3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
DE102011008352A1
(de)
|
2011-01-12 |
2012-07-12 |
Merck Patent Gmbh |
5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
|
DE102011009961A1
(de)
|
2011-02-01 |
2012-08-02 |
Merck Patent Gmbh |
7-Azaindolderivate
|
EA201300997A1
(ru)
|
2011-03-09 |
2014-02-28 |
Мерк Патент Гмбх |
ПИРИДО[2,3-b]ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ТЕРАПЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ
|
CN103732592A
(zh)
|
2011-04-21 |
2014-04-16 |
默沙东公司 |
胰岛素样生长因子-1受体抑制剂
|
SG194105A1
(en)
|
2011-05-23 |
2013-11-29 |
Merck Patent Gmbh |
Pyridine-and pyrazine derivatives
|
ES2871052T3
(es)
|
2011-05-31 |
2021-10-28 |
Rakovina Therapeutics Inc |
Inhibidores tricíclicos de la poli(ADP-ribosa)polimerasa
|
DE102011105469A1
(de)
|
2011-06-24 |
2012-12-27 |
Merck Patent Gmbh |
7-Azaindolderivate
|
WO2013022519A1
(en)
|
2011-08-10 |
2013-02-14 |
Merck Patent Gmbh |
Pyrido-pyrimidine derivatives
|
DE102011112978A1
(de)
|
2011-09-09 |
2013-03-14 |
Merck Patent Gmbh |
Benzonitrilderivate
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
JP6106685B2
(ja)
|
2011-11-17 |
2017-04-05 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
C−jun−n−末端キナーゼ(jnk)の阻害剤
|
DE102011119127A1
(de)
|
2011-11-22 |
2013-05-23 |
Merck Patent Gmbh |
3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
|
SI2812337T1
(sl)
|
2012-02-09 |
2017-01-31 |
Merck Patent Gmbh |
Furo (3,2-b) in tieno (3,2-b) piridinski derivati kot zaviralci tbk1 in ikk
|
DE102012006884A1
(de)
|
2012-04-04 |
2013-10-10 |
Merck Patent Gmbh |
Cyclische Amide als MetAP-2 Inhibitoren
|
WO2013165816A2
(en)
|
2012-05-02 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
BR112015006990A2
(pt)
|
2012-09-28 |
2017-07-04 |
Merck Sharp & Dohme |
composto, composição farmacêutica, e, uso de pelo menos um composto
|
DE102012019369A1
(de)
|
2012-10-02 |
2014-04-03 |
Merck Patent Gmbh |
7-Azaindolderivat
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
USRE48175E1
(en)
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
PT2925888T
(pt)
|
2012-11-28 |
2017-12-13 |
Merck Sharp & Dohme |
Composições e métodos para tratamento do cancro
|
CA2895504A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
US9540377B2
(en)
|
2013-01-30 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as HDM2 inhibitors
|
CN105307656B
(zh)
|
2013-06-06 |
2019-02-19 |
利德发现中心有限责任公司 |
巨噬细胞刺激1受体mst1r的喹啉抑制剂
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
EP3041934A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
US10047070B2
(en)
|
2013-10-18 |
2018-08-14 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
CA2927917C
(en)
|
2013-10-18 |
2022-08-09 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of proliferative diseases
|
US9862688B2
(en)
|
2014-04-23 |
2018-01-09 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
ES2754549T3
(es)
|
2014-12-03 |
2020-04-20 |
Glycomimetics Inc |
Inhibidores heterobifuncionales de E-selectinas y receptores de quimioquinas CXCR4
|
EP3236959A4
(en)
|
2014-12-23 |
2018-04-25 |
Dana Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
AU2016243529B2
(en)
|
2015-03-27 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
AU2016269839B2
(en)
|
2015-06-03 |
2021-07-08 |
The University Of Queensland |
Mobilizing agents and uses therefor
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
JP7028766B2
(ja)
|
2015-09-09 |
2022-03-02 |
ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド |
サイクリン依存性キナーゼの阻害剤
|
US11291678B2
(en)
|
2016-03-02 |
2022-04-05 |
Glycomimetics, Inc |
Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
|
US11066396B2
(en)
|
2016-06-23 |
2021-07-20 |
Merck Sharp & Dohme Corp. |
3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
|
EP3497131B1
(en)
|
2016-08-08 |
2022-03-09 |
GlycoMimetics, Inc. |
Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4.
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
US11072625B2
(en)
|
2016-10-07 |
2021-07-27 |
Glycomimetics, Inc. |
Highly potent multimeric e-selectin antagonists
|
WO2018071283A1
(en)
|
2016-10-12 |
2018-04-19 |
Merck Sharp & Dohme Corp. |
Kdm5 inhibitors
|
WO2018169853A1
(en)
|
2017-03-15 |
2018-09-20 |
Glycomimetics, Inc. |
Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
|
CN110650976B
(zh)
|
2017-04-13 |
2024-04-19 |
赛罗帕私人有限公司 |
抗SIRPα抗体
|
CN110996958B
(zh)
|
2017-08-16 |
2023-05-12 |
默克专利股份有限公司 |
包含5,10-亚甲基-(6r)-四氢叶酸以及二羧酸的稳定的冻干物
|
EP3706742B1
(en)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
EP3717013A1
(en)
|
2017-11-30 |
2020-10-07 |
GlycoMimetics, Inc. |
Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
|
EP3732186A1
(en)
|
2017-12-29 |
2020-11-04 |
GlycoMimetics, Inc. |
Heterobifunctional inhibitors of e-selectin and galectin-3
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
CN111867601A
(zh)
|
2018-03-05 |
2020-10-30 |
糖模拟物有限公司 |
用于治疗急性髓系白血病及相关病症的方法
|
US11874276B2
(en)
|
2018-04-05 |
2024-01-16 |
Dana-Farber Cancer Institute, Inc. |
STING levels as a biomarker for cancer immunotherapy
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020139962A1
(en)
|
2018-12-27 |
2020-07-02 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of e-selectin and galectin-3
|
WO2021041532A1
(en)
|
2019-08-26 |
2021-03-04 |
Dana-Farber Cancer Institute, Inc. |
Use of heparin to promote type 1 interferon signaling
|
MX2022007535A
(es)
|
2019-12-17 |
2022-09-23 |
Merck Sharp & Dohme Llc |
Inhibidores de prmt5.
|